Authors
Latest:
Discussing Current Research in Medullary Thyroid CancerRozita Yarmand, PhD, discusses the take home message from the current research in medullary thyroid cancer.
Latest:
Follow-Up Results for Ruxolitinib in the Second-Line Treatment of PVRuben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses 4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.
Latest:
Data Shows How Ruxolitinib is the Cornerstone of Treatment in MyelofibrosisRuben Mesa, MD, discusses crucial data from the COMFORT studies that show ruxolitinib's benefit in patients with myelofibrosis.
Latest:
Ruxolitinib Appears Promising as Treatment of Chronic Graft-Versus-Host DiseaseRushang D. Patel, MD, discusses the background to the single center experience with ruxolitinib as treatment of patients with chronic graft-versus-host disease.
Latest:
New Therapeutics in Gynecologic CancerRussell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.
Latest:
Olaparib for Patients With DNA Repair Defects and Metastatic Prostate Cancer: Is it Time Yet?Reviewers Commentary: This article adds to the growing body of literature on the role of PARP inhibitors in tumors with DNA repair defects.
Latest:
The Mechanism of Action of TrastuzumabRuth M. O’Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses the mechanism of action of trastuzumab.
Latest:
Treating Breast Cancer in Premenopausal WomenRuth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treating premenopausal women with breast cancer.
Latest:
Comparing Toxicity Profiles of Immunotherapy Versus BRAF-Targeted Therapy in MelanomaRyan J. Sullivan, MD, compares the toxicity profiles of BRAF-targeted therapy and immunotherapy used for the treatment of patients with melanoma.
Latest:
Potential Impact of Tumor Infiltrating Lymphocytes on Melanoma TreatmentRyan Sullivan, MD, explains how tumor infiltrating lymphocytes could impact the melanoma treatment landscape if approved by the FDA.
Latest:
Participating in Multidisciplinary Policy Development for Immuno-OncologyRyan Weight, DO discusses takeaways from the Immuno-Oncology Institute Working Group Summit. The summit was a part of the Association of Community Cancer Centers’ Immuno-Oncology Institute and brought together multidisciplinary working groups to strategize policy and delivery changes for the effective use of immunotherapy.
Latest:
The Significance of PSA Screening by Primary Care PhysiciansRyan Werntz, MD, urologist, Oregon Health and Science University, discusses the significance of prostate-specific antigen (PSA) screening by primary care physicians.
Latest:
The Role of Regorafenib in Colorectal CancerS. Gail Eckhardt, MD, discusses the role of regorafenib in colorectal cancer.
Latest:
Dr. S. Vincent Rajkumar on a New Bortezomib Triplet in Multiple MyelomaS. Vincent Rajkumar, MD, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.
Latest:
Association of Obesity With Metastatic Colorectal CancerS. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the association of obesity with metastatic colorectal cancer.
Latest:
Examining Safety: Daratumumab With VRd in Transplant-Ineligible MyelomaSaad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.
Latest:
Dr. Sabine Siesling on Mastectomies Versus Breast Conserving SurgerySabine Siesling discusses breast conserving surgery versus mastectomy. Siesling says her and her team found that internationally, the survival rate of breast cancer patients is lower when a mastectomy is performed, as compared to breast conserving surgery.
Latest:
Radium-223 in Advanced Prostate CancerThe progression of prostate cancer to castration-resistant prostate cancer is a crucial change in the behavior of this cancer. Bony metastasis is a common finding that may cause symptoms such as pain.
Latest:
The Mechanism of Action of Durvalumab in the Treatment of Urothelial Bladder CancerSaeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses the mechanism of action of the PD-1 antibody durvalumab in a phase I/II dose-escalation and dose-expansion study in the treatment of patients with metastatic urothelial bladder cancer. He also discusses the next steps in this line of research.
Latest:
Dr. Saeed Rafii on the Phase Ib JAVELIN Trial Examining Avelumab in Breast CancerSaeed Rafii, MD, PhD, MRCP, discusses the phase Ib JAVELIN solid tumor trial. The trial looks at the anti-PD-L1 antibody avelumab in patients with locally advanced or metastatic breast cancer.
Latest:
Dr. Safi Shahda on a Phase Ib Study Investigating BBI-608 for mPDAC"This combination seems to be well-tolerated by patients with manageable toxicity, and overall efficacy for the small group seems to be favorable."
Latest:
Necessity of Transplant Considered in Multiple MyelomaSagar Lonial, MD, a professor and Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, and the chief medical officer of Winship Cancer Institute of Emory University, explains the need for transplant in patients with multiple myeloma.
Latest:
Unmet Needs in R/R MM and Clinical Practice PearlsClosing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.
Latest:
A Phase III Study of Paclitaxel With Everolimus in Gastric CancerSalah-Eddin Al-Batran, MD, medical oncologist and Director at the Institute of Clinical Cancer Research, Frankurt, Germany, discusses the findings of a study of paclitaxel with everolimus in gastric cancer.
Latest:
Maisel Reviews Treatment Options for Multiple Myeloma in 2 Case StudiesDuring a <em>Targeted Oncology </em>live case-based peer perspectives program, Christopher Maisel, MD, recently discussed the treatment options and considerations he makes when treating patients with multiple myeloma.
Latest:
The Benefit of In-House Genomic Testing at a Cancer CenterSameek Roychowdhury, MD, PhD, from OSUCCC – James, discusses the benefit of a precision cancer medicine clinic.
Latest:
News Therapies Emerge to Combat Aggressive LymphomasSameer Desai, MD, discusses the changing treatment landscape for lymphomas.
